The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
Masato TakahashiShoichiro OhtaniShigenori E NagaiSeiki TakashimaMiki YamaguchiMichiko TsuneizumiYoshifumi KomoikeTomofumi OsakoYoshinori ItoMasahiko IkedaKazushige IshidaTakahiro NakayamaTsutomu TakashimaTakashi AsakawaSho MatsumotoDaisuke ShimizuNorikazu MasudaPublished in: Breast cancer research and treatment (2020)
Our results suggest similar efficacy and safety for pertuzumab plus trastuzumab and docetaxel in Japanese patients compared with the overall population of CLEOPATRA, providing further support for this combination therapy as standard of care for Japanese patients with inoperable or recurrent HER2-positive breast cancer.